Pharmacological management of obesity improves outcomes and decreases the risk of obesity-related complications. This American Gastroenterological Association guideline is intended to support practitioners in decisions about pharmacological interventions for overweight and obesity. A multidisciplinary pa...
Farrell, B;
Black, C;
Thompson, W;
McCarthy, L;
Rojas-Fernandez, C;
Lochnan, H;
Shamji, S;
Upshur, R;
Bouchard, M;
Welch, V.
OBJECTIVE: To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper, stop, or switch antihyperglycemic agents in older adults. METHODS: We focused on the highest level of evidence available and sought input from primary care professionals in guideline de...
DESCRIPTION: In April 2017, the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the management of type 2 diabetes mellitus. METHODS: The VA/DoD Evidence-Based Practice Work Group convened a joint VA/DoD guideline developme...
DESCRIPTION: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on oral pharmacologic treatment of type 2 diabetes in adults. This guideline serves as an update to the 2012 ACP guideline on the same topic. This guideline is endor...
"OBJECTIVE:
To formulate clinical practice guidelines for the use of continuous glucose monitoring and continuous subcutaneous insulin infusion in adults with diabetes.
PARTICIPANTS:
The participants include an Endocrine Society-appointed Task Force of seven experts, a methodologist, and a medical write...
Glucemia,
Terapia Combinada,
Diabetes Mellitus Tipo 1,
Diabetes Mellitus Tipo 2,
Dieta para Diabéticos,
Monitoreo de Drogas,
Endocrinología,
Hiperglucemia,
Hipoglucemia,
Insulina/uso terapéutico,
Sistemas de Infusión de Insulina,
Monitoreo Ambulatorio,
Educación del Paciente como Asunto,
Medicina de Precisión,
Diabetes Mellitus Tipo 1/tratamiento farmacológico,
Diabetes Mellitus Tipo 2/tratamiento farmacológico,
Diabetes Mellitus Tipo 1/terapia,
Diabetes Mellitus Tipo 2/terapia,
Hipoglucemiantes/uso terapéutico,
Hipoglucemiantes/efectos adversos,
Insulina/efectos adversos
Rahelić, D;
Altabas, V;
Bakula, M;
Balić, S;
Balint, I;
Marković, BB;
Bicanić, N;
Bjelinski, I;
Bozikov, V;
Varzić, SC;
Car, N;
Berković, MC;
Orlić, ZC;
Deskin, M;
Sunić, ED;
Tomić, NG;
Goldoni, V;
Gradiser, M;
Mahecić, DH;
Balen, MJ;
Erzen, DJ;
Majanović, SK;
Kokić', S;
Krnic, M;
Kruljac, I;
Liberati-Cizmek, AM;
Martina, L;
Metelko, Z;
Mirosević, G;
Vrbica, SM;
Renar, IP;
Petric, D;
Prasek, M;
Prpić-Kizevać, I;
Radman, M;
Soldo, D;
Sarić, T;
Tesanović, S;
Kurir, TT;
Wensveen, TT;
Botica, M;
Vrkljan, M;
Rotkvic, VZ;
Zorić, C;
Krznarić, Z.
INTRODUCTION:
The Croatian Association for Diabetes and Metabolic Disorders of the Croatian Medical Association has issued in 2011 the first national guidelines for the nutrition, education, self-control, and pharmacotherapy of diabetes type 2. According to the increased number of available medicines and...
Jacobi, J;
Bircher, N;
Krinsley, J;
Agus, M;
Braithwaite, S. S;
Deutschman, C;
Freire, A. X;
Geehan, D;
Kohl, B;
Nasraway, S. A;
Rigby, M;
Sands, K;
Schallom, L;
Taylor, B;
Umpierrez, G;
Mazuski, J;
Schunemann, H.
Objective: To evaluate the literature and identify important aspects of insulin therapy that facilitate safe and effective infusion therapy for a defined glycemic end point. Methods: Where available, the literature was evaluated using Grades of Recommendation, Assessment, Development, and Evaluation (GRA...